The PETRA01 program aims to develop a new type of treatment for cancer. The program was originally licensed to the company Petra Pharma, which continued the program and identified a clinical candidate for AML (acute myeloid leukemia). Later, the agreement was transferred to the newly started company Ravenna Pharmaceuticals, a spin-out from Petra Pharma, which thus assumed responsibility for the continued development of the program and the financial commitments.
In March 2021, the PETRA01 program was acquired by the American oncology company HiberCell Inc.
Despite positive pre-clinical results, HiberCell discontinued further development in December 2022 due to strategic priorities in its clinical portfolio. The process for the return of the PETRA01 program and all associated documentation and ownership rights is ongoing. Sprint Bioscience continues to see great commercial potential for the program and is preparing to find a new partner as soon as the return is completed.